Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women
- Registration Number
- NCT03212781
- Lead Sponsor
- Assiut University
- Brief Summary
Iron deficiency is the most prevalent nutritional deficiency and the most common cause of anemia .It is characterized by a defect in hemoglobin synthesis, resulting in red blood cells that are abnormally small (microcytic) and contain a decreased amount of hemoglobin (hypochromic).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 66
Inclusion Criteria
- Hemoglobin < 10 g/dL
- Gestational age between 14-28 weeks.
- Willingness to participate and signing the informed consent form.
Exclusion Criteria
- Iron overload or disturbances in utilization of iron
- Decompensated liver cirrhosis and active hepatitis
- Active acute or chronic infections
- History of multiple allergies
- Known hypersensitivity to parenteral iron or any recipients in the investigation drug products
- Erythropoietin treatment within 8 weeks prior to the screening visit
- Other iron treatment or blood transfusion within 4 weeks prior to the screening visit
- Planned elective surgery during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description oral iron Ferrous Fumarate patients will receive oral iron intravenous iron Iron dextran patients will receive intravenous iron as total dose infusion
- Primary Outcome Measures
Name Time Method The change in Hemoglobin concentration from baseline to 8 weeks therapy 8 weeks measure hemoglobin level before and after treatment
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie iron dextran's efficacy in treating iron deficiency anemia during pregnancy compared to oral ferrous fumarate?
How does intravenous iron dextran compare to oral iron supplementation in improving hemoglobin levels in gestational anemia patients?
Are there specific biomarkers that predict response to total dose infusion of iron dextran versus oral iron in iron-deficient pregnant women?
What are the potential adverse events associated with high-dose iron dextran infusion in pregnancy and how are they managed?
How do iron dextran and ferrous fumarate compare to other parenteral iron formulations like ferric carboxymaltose in treating gestational anemia?
Trial Locations
- Locations (1)
Assiut Faculty of Medicine
🇪🇬Assiut, Egypt
Assiut Faculty of Medicine🇪🇬Assiut, Egypt